DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
DBV | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417345 (+3 more)
- LEI:
- 969500PVBQFWQKVDMD80
- Country:
- France
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-04-03 22:05 |
DBV Technologies annonce le lancement d’une offre globale d’actions ordinaires…
|
French | 191.3 KB | ||
| 2019-04-03 22:05 |
DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary…
|
English | 197.6 KB | ||
| 2019-04-01 23:00 |
DBV Technologies Announces Filing of 2018 “Document de Référence” and 2018 Annu…
|
English | 124.2 KB | ||
| 2019-03-06 19:00 |
Monthly information regarding the total number of voting rights and total numb…
|
English | 87.6 KB | ||
| 2019-03-06 19:00 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 97.4 KB | ||
| 2019-03-05 22:10 |
DBV Technologies annonce ses résultats financiers pour l’exercice 2018 et fait …
|
French | 189.7 KB | ||
| 2019-03-05 07:30 |
DBV Technologies Announces Appointment of Michel de Rosen as Non-Executive Chai…
|
English | 143.3 KB | ||
| 2019-03-05 07:30 |
DBV Technologies annonce la nomination de Michel de Rosen en tant que Président…
|
French | 168.7 KB | ||
| 2019-03-01 07:30 |
DBV Technologies to Attend Upcoming Investor Conferences
|
English | 155.4 KB | ||
| 2019-03-01 07:30 |
DBV Technologies invitée à présenter lors de prochaines conférences Investisseu…
|
French | 159.1 KB | ||
| 2019-02-27 16:57 |
Franchissements de seuils
|
French | 27.5 KB | ||
| 2019-02-22 17:00 |
DBV Technologies annonce la publication des résultats détaillés de l’essai clin…
|
French | 217.2 KB | ||
| 2019-02-22 17:00 |
DBV Technologies Announces Publication of Detailed Phase III Trial Results Eval…
|
English | 186.7 KB | ||
| 2019-02-21 15:39 |
Franchissement de seuils
|
French | 24.0 KB | ||
| 2019-02-13 22:00 |
DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the…
|
English | 141.7 KB |
Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-09 | N/A | Other | Other | 2,483,161 | 7,449,483.00 EUR |
Peer Companies
